Bronchogen vs Crystagen
Moderate Research vs Moderate Research
compatible Both have immune-modulating properties; different tissue targets.
Molecular Data
Bronchogen Crystagen
Weight 432 Da 359 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes Minutes (short peptide); effects persist via epigenetic changes
Chain 4 amino acids 3 amino acids
Type Tetrapeptide bioregulator Tripeptide bioregulator
Key Benefits
Bronchogen
01 Supports bronchial tissue function
02 Regulates protein synthesis in lungs
03 Targets bronchopulmonary system
04 Maintains respiratory epithelium
05 Part of Khavinson bioregulator family
06 Epigenetic mechanism of action
07 Tissue-specific targeting
08 Well-tolerated in research
Crystagen
01 Normalizes immune function in 82% of patients
02 Stimulates normal lymphocyte proliferation
03 Inhibits tumor cell growth (antitumor activity)
04 Doubles HSP gene expression (stress resistance)
05 Reduces respiratory viral infections
06 Activates B-cell immune system
07 Normalizes IL-6 expression
08 Effective after radiation/chemotherapy
Dosing Protocols
Bronchogen
10-20 mg oral or 10 mg injectable / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10 days
Crystagen
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
Side Effects
Bronchogen
Generally well-tolerated
Minimal side effects reported
Crystagen
Generally well-tolerated
Minimal side effects reported
Contraindications
Active respiratory emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Active autoimmune flares (consult physician)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Bronchogen Crystagen
Status Moderate Research Moderate Research
References 3 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.